FEATURED EDITORIAL
We caught up with Joel Stanley, founder and CEO of AJNA Biosciences, to talk about botanical drug development.
- Organizing Digital Systems Around Novel Modalities
- The Future Is Ancient: Evolution, Metabolics, And AI
- The Next Chapter Of Obesity And Type 2 Diabetes Care: ADA 2026 Signals A More Personalized Future
- Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire
- Aligning Standards, Validation, And Governance For Digital Preclinical Research
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- Can Molecular Glue Degraders Make The Undruggable Druggable?
FEATURED APPLICATION CONTENT
-
Personalized medicine struggles with models that fail to reflect real human biology. Organ-on-a-Chip systems recreate tissue complexity, helping predict patient-specific treatment responses.
-
Modeling the human brain requires more than simplified systems. New approaches that incorporate diverse cell types are improving how researchers study neurovascular function with greater precision.
-
Centralizing data unlocks faster insights, reduces duplicated effort, and improves compliance. By overcoming silos and “dark data,” organizations can enable efficient search, reuse, and analysis.
-
See how existing partnerships with NIH allowed the chance to bring together government, academic, and industry resources through strategic initiatives that streamline processes and maximize benefits.
-
See how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
Integrated accelerated stability workflows reduce manual data handling while improving confidence in shelf‑life predictions. Help your teams move faster with fewer experimental demands.
-
Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
-
Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
-
Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
-
Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
-
Automated structure verification integrated into open-access NMR workflows cuts review time dramatically while maintaining confidence in results. See how smart parameter optimization improves efficiency.
-
High-throughput chemistry delivers speed and efficiency, but only with the right digital backbone. See how integrated automation and analytics help chemists extract more value from every plate.
- iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
- How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 Of 3)
- 2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics
- 2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Altruist Biologics' Hangzhou Antibody-Drug Conjugate Facility Receives Provincial Regulatory Approval For Segmented Production
- Saol Therapeutics Resubmits The New Drug Application For SL1009 (DCA) For The Treatment Of Pyruvate Dehydrogenase Complex Deficiency (PDCD), An Ultra-Rare Disease
- Altasciences And Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough
- Certara Accelerates Drug Discovery And Development With NVIDIA BioNeMo Agent Toolkit
- Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery With Broad Analysis And International AI Initiative
- The University Of Colorado Anschutz, Along With UCHealth And Children's Hospital Colorado, Form Strategic Alliance With Bayer To Advance Drug Development And Clinical Trials
- Helix Announces Multi-Year Agreement With AstraZeneca To Support Genomic Research For Drug Discovery And Development
- Aureka Releases OpenDDE, An Open-Source Drug Discovery Engine Designed To Accelerate AI-Driven Therapeutic Discovery
- Ascletis Submits Two IND Applications To The U.S. FDA For The Treatment Of Obesity: ASC36 Once-Monthly Injection, A Peptide Amylin Receptor Agonist, And ASC36_35 FDC Once-Monthly Injection, A Co-Formulation Of ASC36 Plus Peptide GLP-1R/GIPR Agonist ASC35
- INTENT Biologics Receives FDA Breakthrough Therapy Designation For PEP Biologic For Its Phase 3 Ready Flagship Indication
ARCHIVED NEWSLETTER
- 07.07.26 -- Discovery Dialogues: Winston Haynes, VP, Computational Sciences And Engineering, LabGenius Tx
- 07.03.26 -- Drug Discovery Online Best Of June
- 06.30.26 -- A New De Novo Protein Design Platform For GPCR Drug Discovery
- 06.24.26 -- How Spray Drying Is Reshaping Modern Drug Development
- 06.16.26 -- Fostering Entrepreneurial Mentorship And Education: A Peek Into Nucleate Boston Activator 2026 Cohort
